Ribociclib

Trade Name: 
Kisqali
Manufacturer/Distributor: 
Novartis Pharmaceuticals Canada Inc.
Classification: 
Antineoplastic agent
ATC Class: 
L01EX42 - ribociclib
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2018/03/02
Date Marketed in Canada (yyyy/mm/dd): 
2018/11/26
Presentation: 
Tablet: 200 mg. DIN: 02473569
Comments: 
For use in combination with letrozole for treatment of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
Source: 
Product monograph